High visualization, ease of use and greater pain reduction for up to 30 days after cataract surgery led to higher patient and physician ratings for Dextenza compared with placebo, according to a speaker.
“Clinical visualization allows for consistent postoperative treatment and monitoring by multiple health care professionals and results in a positive patient experience with Dextenza,” Cathleen M. McCabe, MD, said at the virtual American Society of Cataract and Refractive Surgery meeting.
There is a need for sustained-release therapies after ophthalmic surgery, McCabe said. Eye drops
Uncategorized